Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 201–300 of 3,704
Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists
Barrett, T. S., Hafermann, J. O., Richards, S., LeJeune, K., & Eid, G. M. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.3590 · Cited by 87
Weight reduction and the impact on apnea-hypopnea index: A systematic meta-analysis
Malhotra, A., Heilmann, C. R., Banerjee, K. K., Dunn, J. P., Bunck, M. C. M., & Bednařík, J. (2024) · Sleep Medicine · doi:10.1016/j.sleep.2024.06.014 · Cited by 105
“, Fourth some agents, including glucagon-like peptide-1 receptor agonists (GLP-1 RA’s) and GLP-1 RA/GIP agonists are relatively new [36].”
Self-citationSubramaniyan, V., & Hanim, Y. U. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01729-1 · Cited by 112
Tan, B., Pan, X.-H., Chew, H. S. J., Goh, R. S. J., Lin, C., Anand, V. V., Lee, E. C. Z., Chan, K. E., Kong, G., Ong, C. E. Y., et al. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01321-5 · Cited by 83
Mesinovic, J., Fyfe, J. J., Talevski, J., Wheeler, M. J., Leung, G. K. W., George, E. S., Hunegnaw, M. T., Glavas, C., Jansons, P., Daly, R. M., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0112 · Cited by 114
“Tirzepa-tide leads to similar improvements in the abovementioned outcomes in individuals with overweight and obesity over a similar timeframe [192].”
BackgroundHandelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Self-citationZhang, X., Lau, H. C.-H., & Yu, J. Q. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100018 · Cited by 112
Rosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 140
Gallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
“Frontiers in Endocrinology 09 study at 72 weeks were the percentage change in weight from baseline and a body weight reduction of 5% or more (82).”
BackgroundMethodInfluentialManagement of NAFLD in primary care settings
Wong, V. W. S., Zelber‐Sagi, S., Cusi, K., Carrieri, P., Wright, E., Crespo, J., & Lazarus, J. V. (2022) · Liver International · doi:10.1111/liv.15404 · Cited by 81
2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure
Kittleson, M. M., Benjamin, E. J., Blumer, V., Harrington, J., Januzzi, J. L., McMurray, J. J. V., & Vest, A. R. (2025) · JACC · doi:10.1016/j.jacc.2025.05.008 · Cited by 79
Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update
Pedersen, S. D., Manjoo, P., Dash, S., Jain, A., Pearce, N., & Poddar, M. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.250502 · Cited by 78
Hurt, R. T., Stephenson, C. R., Gilman, E. A., Aakre, C. A., Croghan, I. T., Mundi, M. S., Ghosh, K., & Edakkanambeth Varayil, J. (2025) · Journal of Primary Care & Community Health · doi:10.1177/21501319251332215 · Cited by 78
Bays, H. E., Kirkpatrick, C. F., Maki, K. C., Toth, P. P., Morgan, R. T., Tondt, J., Christensen, S. M., Dixon, D. L., & Jacobson, T. A. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100108 · Cited by 128
Longitudinal Analysis of Obesity Drug Use and Public Awareness
Berning, P., Adhikari, R., Schroer, A. E., Jelwan, Y. A., Razavi, A. C., Blaha, M. J., & Dzaye, O. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.57232 · Cited by 78
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
Hwang, J. H., Laiteerapong, N., Huang, E. S., & Kim, D. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.5586 · Cited by 77
Enteroendocrine cell regulation of the gut-brain axis
Barton, J. R., Londregan, A., Alexander, T. D., Entezari, A. A., Covarrubias, M., & Waldman, S. A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1272955 · Cited by 102
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Kokkorakis, M., Muzurović, E., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 76
Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years
Schiavon, C. A., Cavalcanti, A. B., Oliveira, J. D., Machado, R. H. V., Santucci, E. V., Santos, R. N., Oliveira, J. S., Damiani, L. P., Junqueira, D., Halpern, H., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.11.032 · Cited by 76
Dahl, K., Toubro, S., Dey, S., Duque do Vale, R., Flint, A., Gasiorek, A., Heydorn, A., Jastreboff, A. M., Key, C., Petersen, S. B., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01185-7 · Cited by 80
Self-citationMoll, H., Frey, E., Gerber, P., Geidl, B., Kaufmann, M., Braun, J., Beuschlein, F., Puhan, M. A., & Yebyo, H. G. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102661 · Cited by 73
Obesity accelerates cardiovascular ageing
Ruperez, C., Madeo, F., de Cabo, R., Kroemer, G., & Abdellatif, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf216 · Cited by 73
“259,260 Indeed, in a Phase 3 trial, tirzepatide treatment of patients with obesity and HFpEF significantly lowered the risk of cardiovascular death and heart failure worsening.”
Qin, W., Yang, J., Deng, C., Ruan, Q., & Duan, K. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15386 · Cited by 72
“In summary, the collective results from the STEP clinical trial programme suggest that semaglutide 2. from the latest SURMOUNT-1 47 and SURMOUNT-2 48 trials show that tirzepatide is the most promising drug on the horizon for obesity treatment.”
ResultInfluentialTirzepatide Once Weekly for the Treatment of Obesity
(2022) · New England Journal of Medicine · doi:10.1056/nejmc2211120 · Cited by 71
One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice
Gasoyan, H., Pfoh, E. R., Schulte, R., Le, P., Butsch, W. S., & Rothberg, M. B. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.33326 · Cited by 71
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
“77 Other dual co-agonists acting on GLP-1/amylin receptors and GLP-1/ glucagon receptors are also being assessed in early phase clinical trials as potential treatments for obesity and metabolic complications.”
BackgroundPan, X., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M., Khoo, C. M., Mehta, A., Majety, P., et al. (2024) · Obesity · doi:10.1002/oby.24002 · Cited by 71
“3.0% to 8.6%, with significant adverse side effects [66, 70, 71].”
BackgroundInfluentialJeong, B.-K., Choi, W., Choi, W., Moon, J., Lee, W. H., Choi, C., Choi, I. Y., Lee, S.-H., Kim, P., Ju, Y. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50660-y · Cited by 90
“While tirzepatide is an effective treatment for T2DM and obesity 14 – 16 with signi fi cant promise as a therapeutic option for MASLD 17 , its potential long-term bene fi ts in preventing the progression to advanced fi brosis or HCC are unknown.”
Levi, J., Wang, J., Venter, F., & Hill, A. (2023) · Obesity · doi:10.1002/oby.23725 · Cited by 69
“We also searched for data on oral semaglutide, which has demonstrated good weight loss effects in clinical trials and which is sometimes used off-label for treatment of obesity in the absence of diabetes, and the new subcutaneous medication tirzepatide, which is FDA approved for use in T2DM but is currently not yet ap…”
BackgroundResultInfluentialTreating chronic diseases without tackling excess adiposity promotes multimorbidity
Sattar, N., McMurray, J. J. V., McInnes, I. B., Aroda, V. R., & Lean, M. E. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00317-5 · Cited by 69
The Significance of Hypothalamic Inflammation and Gliosis for the Pathogenesis of Obesity in Humans
SEWAYBRICKER, L. E., Huang, A., Chandrasekaran, S., Melhorn, S. J., & Schur, E. A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac023 · Cited by 84
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 77
“%) with placebo ( P < 0.001) (85) and has been recently approved for the treatment of obesity.”
BackgroundInfluentialObesity: Recent Advances and Future Perspectives
Janić, M., Janež, A., El‐Tanani, M., & Rizzo, M. (2025) · Biomedicines · doi:10.3390/biomedicines13020368 · Cited by 97
“The incidence of adverse events that led to the discontinuation of treatment occurred in 4.3%, 7.1%, and 6.2% of participants who received 5, 10, and 15 mg of tirzepatide, respectively, compared to 2.6% in the placebo cohort [12].”
InfluentialZeng, Q., Xu, J., Mu, X., Shi, Y., Fan, H., & Li, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1214334 · Cited by 66
“Of the 52 excluded records, 28 were duplicates, 15 had no results, 3 had a study duration of less than 24 weeks, 2 were non-RCTs and one did not include patients with T2D; the remaining nine studies (29 – 31, 34 – 39) satis fi ed the inclusion criteria and were included.”
BackgroundResultInfluentialYu, X., Chen, S., Funcke, J.-B., Straub, L. G., Pirro, V., Emont, M. P., Droz, B. A., Collins, K. A., Joung, C., Pearson, M. J., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.11.003 · Cited by 67
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“Tirzepatide, a novel ‘twincretin’ targeting both GLP-1 and GIP receptors, has demonstrated efficacy for treating T2DM in the SURPASS clinical trial program [168] and overweight/obesity in the SURMOUNT studies [169].”
BackgroundEffectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
NAFLD, MAFLD and obesity: brothers in arms?
Machado, M. V., & Cortez‐Pinto, H. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00717-4 · Cited by 81
Mashayekhi, M., Nian, H., Mayfield, D., Devin, J. K., Gamboa, J. L., Yu, C., Silver, H. J., Niswender, K. D., Luther, J. M., & Brown, N. J. (2023) · Diabetes · doi:10.2337/db23-0356 · Cited by 83
JAKICIC, J. M., APOVIAN, C. M., BARR-ANDERSON, D. J., COURCOULAS, A. P., DONNELLY, J. E., EKKEKAKIS, P., HOPKINS, M., LAMBERT, E. V., NAPOLITANO, M. A., & VOLPE, S. L. (2024) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003520 · Cited by 68
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Krüger, N., Schneeweiss, S., Fuse, K., Matseyko, S., Sreedhara, S. K., Hahn, G., Schunkert, H., & Wang, S. V. (2025) · JAMA · doi:10.1001/jama.2025.14092 · Cited by 66
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes
Garg, S. K., Akturk, H. K., Kaur, G., Beatson, C., & Snell-Bergeon, J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0050 · Cited by 65
Vosoughi, K., Salman Roghani, R., & Camilleri, M. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100456 · Cited by 65
Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation
Ravussin, E., Sanchez-Delgado, G., Martin, C. K., Beyl, R. A., Greenway, F. L., O’Farrell, L. S., Roell, W. C., Qian, H.-R., Li, J., Nishiyama, H., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.03.011 · Cited by 72
Tirzepatide and prevention of chronic kidney disease
Bosch, C., Carriazo, S., Soler, M. J., Ortiz, A., & Fernandez-Fernandez, B. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfac274 · Cited by 60
“WHAT IS NEW ABOUT TIRZEPATIDE? The results of RCTs testing tirzepatide in overweight/obesity were recently reported [2].”
BackgroundInfluentialde Lemos, J. A., Linetzky, B., le Roux, C. W., Laffin, L. J., Vongpatanasin, W., Fan, L., Hemmingway, A., Ahmad, N. N., Bunck, M. C., & Stefanski, A. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.22022 · Cited by 64
Self-citationImpact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia
Memel, Z., Gold, S. L., Pearlman, M., Muratore, A., & Martindale, R. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00649-w · Cited by 63
“Neither trial measured baseline hormone levels, including testosterone in men [5, 90].”
Jungnik, A., Arrubla Martinez, J., Plum‐Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14948 · Cited by 63
“Indeed, nausea, among other GI disorders, is also reported with dual GIP/GLP-1RAs and other GCGR/GLP-1RAs in people with overweight/obesity.(39,40,42) Importantly, in our studies, BI 456906 showed clinically significant and meaningful body weight loss (>5%(49)) at 6 weeks' treatment and, at 16 weeks' treatment, placeb…”
BackgroundDual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes
Scheen, A. J. (2023) · Annales d'Endocrinologie · doi:10.1016/j.ando.2022.12.423 · Cited by 63
Sleep Apnea, Obesity, and Diabetes — an Intertwined Trio
Kurnool, S., McCowen, K. C., Bernstein, N., & Malhotra, A. (2023) · Current Diabetes Reports · doi:10.1007/s11892-023-01510-6 · Cited by 84
Haddad, A. J., Suter, M., Greve, J. W. M., Shikora, S. A., Prager, G., Dayyeh, B. K. A., Neto, M. G., Grothe, K. B., Herrera, M. F., Kow, L., et al. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07489-7 · Cited by 85
“Finally, we are living in the dawn of a new era of OMMs, with excellent weight loss outcomes and acceptable safety profiles [152–154].”
Gilbert, O., Gulati, M., Gluckman, T. J., Kittleson, M. M., Rikhi, R., Saseen, J. J., & Tchang, B. G. (2025) · JACC · doi:10.1016/j.jacc.2025.05.024 · Cited by 65
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 79
“However, the placebo group only experienced a 3% decrease in body weight [217].”
BackgroundMethodInfluentialRevised definition of obesity in Asian Indians living in India
Misra, A., Vikram, N. K., Ghosh, A., Ranjan, P., & Gulati, S. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.102989 · Cited by 77
Heymsfield, S. B., Aronne, L. J., Montgomery, P., Klickstein, L. B., Coleman, L. A., Dole, K., Mindeholm, L., Spruill, S. E., Li, X., Attie, K. M., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04204-0 · Cited by 102
Self-citationMilder, D. A., Milder, T. Y., Liang, S. S., & Kam, P. C. A. (2024) · Anaesthesia · doi:10.1111/anae.16306 · Cited by 62
“%) at higher doses of15 mg [46].”
Differential mechanisms affecting weight loss and weight loss maintenance
Rosenbaum, M., & Foster, G. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00864-1 · Cited by 61
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Gutgesell, R. M., Nogueiras, R., Tschöp, M. H., & Müller, T. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01566-x · Cited by 61
“In its phase 3 trial in adults with obesity, the highest dose of 15 mg once weekly produced an average reduction in body weight of 22.5% after 72 weeks of treatment [91], and a 15.7% reduction in body weight in patients with obesity and diabetes [92].”
BackgroundInfluentialCho, Y. K., Lee, Y. L., & Jung, C. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.3.213 · Cited by 71
Mutruc, V., Bologa, C., Șorodoc, V., Ceasovschih, A., Morărașu, B. C., Șorodoc, L., Catar, O., & Lionte, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082833 · Cited by 89
“In the long term, tirzepatide reduced the risk of T2D by 93% and maintained a weight loss of 17.8% even after stopping therapy [109].”
InfluentialMartin, C. K., Carmichael, O. T., Carnell, S., Considine, R. V., Kareken, D. A., Dydak, U., Mattes, R. D., Scott, D., Shcherbinin, S., Nishiyama, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03774-9 · Cited by 97
“A 72-week phase 3 study in adults with obesity demonstrated that once-weekly tirzepatide produced weight reduction of up to 20.9%, compared to 3.1% with placebo 15 .”
InfluentialGlucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Alkabbani, W., Suissa, K., Gu, K. D., Cromer, S. J., Paik, J. M., Bykov, K., Hobai, I., Thompson, C. C., Wexler, D. J., & Patorno, E. (2024) · BMJ · doi:10.1136/bmj-2024-080340 · Cited by 60
Efficacy and safety of semaglutide for weight management: evidence from the STEP program
Amaro, A., Sugimoto, D., & Wharton, S. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2147326 · Cited by 60
Self-citationWeight loss efficiency and safety of tirzepatide: A Systematic review
Lin, F., Yu, B., Ling, B., Lv, G., Shang, H., Zhao, X., Jie, X., Chen, J., & Li, Y. (2023) · PLOS ONE · doi:10.1371/journal.pone.0285197 · Cited by 60
Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications
Chandiwana, N. C., Siedner, M. J., Marconi, V. C., Hill, A. M., Ali, M. K., Batterham, R. L., & Venter, F. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad411 · Cited by 74
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Abasheva, D., Ortíz, A., & Fernández‐Fernández, B. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae296 · Cited by 70
Díaz, L. A., Arab, J. P., Idalsoaga, F. J., Perelli, J., Vega, J. A., Dirchwolf, M., Carreño, J., Samith, B., Valério, C. M., Moreira, R. O., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101903 · Cited by 86
“Tirzepatide is a dual GLP-1/GIP receptor agonist molecule with synergistic activity that has exhibited a greater reduction in body weight and blood glucose than other molecules [140].”
de Mesquita, Y. L. L., Pera Calvi, I., Reis Marques, I., Almeida Cruz, S., Padrao, E. M. H., Carvalho, P. E. D. P., da Silva, C. H. A., Cardoso, R., Moura, F. A., & Rafalskiy, V. V. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01337-x · Cited by 59
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Chong, K., Chang, J. K.-J., & Chuang, L. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12800 · Cited by 84
“39 The use of Tirzepatide q.w. to treat obesity in individuals with type 2 diabetes (SURMOUNT-2) produces a reduction of 12.8% to 14.7% in body weight for a dose of 10 to 15 mg tirzepatide q.w. 40 These results are significantly better than those for subcutaneous semaglutide 2.4 mg q.w. 41 and…”
BackgroundInfluentialWeight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“Recent studies have now demonstrated the strongest weight loss effect with the dual agonist for GLP-1 and GIP, upwards of 22% over 1 year [134].”
InfluentialChao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58
Motta, B. M., Masarone, M., Torre, P., & Persico, M. (2023) · Cancers · doi:10.3390/cancers15225458 · Cited by 66
Akturk, H. K., Dong, F., Snell-Bergeon, J. K., Karakus, K. E., & Shah, V. N. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231223991 · Cited by 58
Semaglutide and blood pressure: an individual patient data meta-analysis
Kennedy, C., Hayes, P., Cicero, A. F. G., Dobner, S., Le Roux, C. W., McEvoy, J. W., Zgaga, L., & Hennessy, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae564 · Cited by 58
Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US
Kim, C., Ross, J. S., Jastreboff, A. M., Meeker, D., Freedman, H., Krumholz, H. M., & Lu, Y. (2025) · JAMA · doi:10.1001/jama.2025.4735 · Cited by 74
Self-citationMetabolically healthy obesity: Misleading phrase or healthy phenotype?
Tanrıöver, C., Çöpür, S., Gaipov, A., Özlüşen, B., Akcan, R. E., Kuwabara, M., Hornum, M., van Raalte, D. H., & Kanbay, M. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.02.025 · Cited by 71
Ganeshalingam, A. A., Uhrenholt, N. G., Arnfred, S., Gæde, P., Düring, S. W., Stenager, E. N., Bünger, N., Pedersen, A. K., Bilenberg, N., & Frystyk, J. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.2332 · Cited by 78
Treating inflammation to combat non-alcoholic fatty liver disease
Wiering, L., & Tacke, F. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0194 · Cited by 56
Jamal, M. H., Alhashemi, M., Dsouza, C. L., Al-Hassani, S., Qasem, W., Almazeedi, S. M., & Al-Sabah, S. K. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07137-0 · Cited by 74
“The lack of significant associations between weight loss and other patient characteristics contrasts with prior research that found a range of sociodemographic, clinical, and other patient-level factors to be major predictors of clinical efficacy and effectiveness [10, 14, 32].”
Therapeutic advances in obesity management: an overview of the therapeutic interventions
Roomy, M. A., Hussain, K., Behbehani, H. M., Abu-Farha, J., Al-Harris, R., Ambi, A. M., Abdalla, M. A., Al‐Mulla, F., Abu‐Farha, M., & Abubaker, J. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1364503 · Cited by 79
Qin, W., Yang, J., Ni, Y., Deng, C., Ruan, Q., Ruan, J., Zhou, P., & Duan, K. (2024) · Endocrine · doi:10.1007/s12020-024-03896-z · Cited by 55
“The majority of the research analyzed the effectiveness of tirzepatide in treating T2D, with BW alteration as a secondary outcome, except for SURMOUNT-1 [12] and SURMOUNT-2 [20], which primarily tested tirzepatide for the treatment of obesity.”
BackgroundMethodResultInfluentialLaddu, D., Neeland, I. J., Carnethon, M., Stanford, F. C., Mongraw-Chaffin, M., Barone Gibbs, B., Ndumele, C. E., Longenecker, C. T., Chung, M. L., Rao, G., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001221 · Cited by 62
“31a However, obesity pharma-cotherapies continue to be dramatically underprescribed.”
BackgroundMalandrino, N., Bhat, S. Z., Alfaraidhy, M., Grewal, R. S., & Kalyani, R. R. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.10.001 · Cited by 76
Gilden, A. H., Catenacci, V. A., & Taormina, J. M. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202405210 · Cited by 60
GLP-1 programs the neurovascular landscape
Chen, B., Yu, X., HORVATH-DIANO, C., Ortuño, M. J., Tschöp, M. H., Jastreboff, A. M., & Schneeberger, M. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.003 · Cited by 62
Self-citationOld, V. J., Davies, M. J., Papamargaritis, D., Choudhary, P., & Watson, E. L. (2025) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13677 · Cited by 55
Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials
Kanbay, M., Copur, S., Siriopol, D., Yildiz, A. B., Gaipov, A., van Raalte, D. H., & Tuttle, K. R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15272 · Cited by 56
Management of metabolic-associated fatty liver disease: The diabetology perspective
Jeeyavudeen, M. S., Khan, S. K., Fouda, S., & Pappachan, J. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i1.126 · Cited by 54
Current and future pharmacotherapies for obesity in children and adolescents
Kelly, A. S. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00858-9 · Cited by 54
Xia, Y., Jin, J., Sun, Y., Kong, X., Shen, Z., Yan, R., Huang, R., Liu, X., Xia, W., Ma, J., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113499 · Cited by 78
Implications of a New Obesity Definition Among the All of Us Cohort
Fourman, L. T., Awwad, A., Gutiérrez‐Sacristán, A., Dash, C. A., Johnson, J. E., Thistle, A. K., Chahal, N., Stockman, S. L., Toribio, M. P., Anekwe, C. V., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.37619 · Cited by 72
Xie, Z., Zheng, G., Liang, Z., Li, M., Deng, W., & Cao, W. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156038 · Cited by 54
Brain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
Proportion of caloric restriction‐induced weight loss as skeletal muscle
Heymsfield, S. B., Yang, S., McCarthy, C., Brown, J. B., Martin, C. K., Redman, L. M., Ravussin, E., Shen, W., Müller, M. J., & Bosy‐Westphal, A. (2024) · Obesity · doi:10.1002/oby.23910 · Cited by 53
Gigliotti, L., Warshaw, H., Evert, A., Dawkins, C., Schwartz, J., Susie, C., Kushner, R., Subramanian, S., Handu, D., & Rozga, M. (2025) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2024.10.023 · Cited by 53
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Wilson, J. M., Hemmingway, A., Cherney, D. Z. I., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0261 · Cited by 53
Caruso, I., Di Gioia, L., Di Molfetta, S., Cignarelli, A., Palmer, S. C., Natale, P., Strippoli, G. F. M., Perrini, S., Natalicchio, A., Laviola, L., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102181 · Cited by 54
Pharmacotherapy for obesity: moving towards efficacy improvement
Coutinho, W. F., & Halpern, B. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01233-4 · Cited by 70
“In SURMOUNT-1, 2539 individuals with obesity or overweight with a weight-related comorbidity (non-diabetes) were randomized to receive tirzepatide or placebo, for 72 weeks [117, 118].”
Lopez‐Yus, M., Horndler, C., Ansón, S. B., Monterde, V. B., & Arbonés-Mainar, J. M. (2024) · Cells · doi:10.3390/cells13050380 · Cited by 63
“Genetic Modification of ADMSC: CRISPR/Cas9 Gene Editing Genetic engineering of ADMSC has been proposed as a strategy to enhance the therapeutic potential of these cells and improve the clinical outcomes after transplantation.”
Background
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.